Exact Mass: 911.4948

Exact Mass Matches: 911.4948

Found 41 metabolites which its exact mass value is equals to given mass value 911.4948, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Kinetensin 1-7

(2S)-2-({[(2S)-1-[(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S)-2-{[(2S,3S)-2-amino-1-hydroxy-3-methylpentylidene]amino}-1-hydroxypropylidene]amino}-5-carbamimidamido-1-hydroxypentylidene]amino}-5-carbamimidamido-1-hydroxypentylidene]amino}-3-(1H-imidazol-5-yl)propanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-3-(4-hydroxyphenyl)propanoate

C41H65N15O9 (911.5089)


Kinetensin 1-7 is a fraction of kinetensin with only the Ile-Ala-Arg-Arg-His-Pro-Tyr peptide chain. Kinetensin is a nonapeptide, originally isolated from pepsin-treated plasma that shares some sequence homology with the C-terminal end of neurotensin, serum albumin, and angiotensin. It is a potent histamine releaser in rodents and may serve as an inflammatory mediator. Kinetensin 1-7 is a fraction of Kinetensin with only Ile-Ala-Arg-Arg-His-Pro-Tyr peptide chain.

   

CDP-DG(a-13:0/i-16:0)

{[(2R,3R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}({hydroxy[(2R)-3-[(10-methyldodecanoyl)oxy]-2-[(14-methylpentadecanoyl)oxy]propoxy]phosphoryl}oxy)phosphinic acid

C41H75N3O15P2 (911.4673)


CDP-DG(a-13:0/i-16:0) is a cytidine diphosphate diacylglycerol or CDP-diacylglycerol (CDP-DG). CDP-diacylglycerol is an important branchpoint intermediate in eukaryotic phospholipid biosynthesis and could be a key regulatory molecule in phospholipid metabolism. It is a glycerophospholipid in which a cytidine diphosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. CDP-DG(a-13:0/i-16:0), in particular, consists of one chain of anteisotridecanoic acid at the C-1 position and one chain of isohexadecanoic acid at the C-2 position. Cytidine diphosphate diacylglycerols are rarely noticed in analyses of lipid compositions of tissues, as they are present is such small amounts (perhaps only 0.05\\% or so of the total phospholipids).

   

CDP-DG(a-15:0/i-14:0)

{[(2R,3R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}({hydroxy[(2R)-3-[(12-methyltetradecanoyl)oxy]-2-[(12-methyltridecanoyl)oxy]propoxy]phosphoryl}oxy)phosphinic acid

C41H75N3O15P2 (911.4673)


CDP-DG(a-15:0/i-14:0) is a cytidine diphosphate diacylglycerol or CDP-diacylglycerol (CDP-DG). CDP-diacylglycerol is an important branchpoint intermediate in eukaryotic phospholipid biosynthesis and could be a key regulatory molecule in phospholipid metabolism. It is a glycerophospholipid in which a cytidine diphosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. CDP-DG(a-15:0/i-14:0), in particular, consists of one chain of anteisopentadecanoic acid at the C-1 position and one chain of isotetradecanoic acid at the C-2 position. Cytidine diphosphate diacylglycerols are rarely noticed in analyses of lipid compositions of tissues, as they are present is such small amounts (perhaps only 0.05\\% or so of the total phospholipids).

   

CDP-DG(a-17:0/i-12:0)

{[(2R,3R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}({hydroxy[(2R)-3-[(14-methylhexadecanoyl)oxy]-2-[(10-methylundecanoyl)oxy]propoxy]phosphoryl}oxy)phosphinic acid

C41H75N3O15P2 (911.4673)


CDP-DG(a-17:0/i-12:0) is a cytidine diphosphate diacylglycerol or CDP-diacylglycerol (CDP-DG). CDP-diacylglycerol is an important branchpoint intermediate in eukaryotic phospholipid biosynthesis and could be a key regulatory molecule in phospholipid metabolism. It is a glycerophospholipid in which a cytidine diphosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. CDP-DG(a-17:0/i-12:0), in particular, consists of one chain of anteisoheptadecanoic acid at the C-1 position and one chain of isododecanoic acid at the C-2 position. Cytidine diphosphate diacylglycerols are rarely noticed in analyses of lipid compositions of tissues, as they are present is such small amounts (perhaps only 0.05\\% or so of the total phospholipids).

   

CDP-DG(i-12:0/a-17:0)

{[(2R,3R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}({hydroxy[(2R)-2-[(14-methylhexadecanoyl)oxy]-3-[(10-methylundecanoyl)oxy]propoxy]phosphoryl}oxy)phosphinic acid

C41H75N3O15P2 (911.4673)


CDP-DG(i-12:0/a-17:0) is a cytidine diphosphate diacylglycerol or CDP-diacylglycerol (CDP-DG). CDP-diacylglycerol is an important branchpoint intermediate in eukaryotic phospholipid biosynthesis and could be a key regulatory molecule in phospholipid metabolism. It is a glycerophospholipid in which a cytidine diphosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. CDP-DG(i-12:0/a-17:0), in particular, consists of one chain of isododecanoic acid at the C-1 position and one chain of anteisoheptadecanoic acid at the C-2 position. Cytidine diphosphate diacylglycerols are rarely noticed in analyses of lipid compositions of tissues, as they are present is such small amounts (perhaps only 0.05\\% or so of the total phospholipids).

   

CDP-DG(i-12:0/i-17:0)

{[(2R,3R,5R)-3,4-dihydroxy-5-(2-hydroxy-4-imino-1,4-dihydropyrimidin-1-yl)oxolan-2-yl]methoxy}({hydroxy[(2R)-2-[(15-methylhexadecanoyl)oxy]-3-[(10-methylundecanoyl)oxy]propoxy]phosphoryl}oxy)phosphinate

C41H75N3O15P2 (911.4673)


CDP-DG(i-12:0/i-17:0) is a cytidine diphosphate diacylglycerol or CDP-diacylglycerol (CDP-DG). CDP-diacylglycerol is an important branchpoint intermediate in eukaryotic phospholipid biosynthesis and could be a key regulatory molecule in phospholipid metabolism. It is a glycerophospholipid in which a cytidine diphosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. CDP-DG(i-12:0/i-17:0), in particular, consists of one chain of isododecanoic acid at the C-1 position and one chain of isoheptadecanoic acid at the C-2 position. Cytidine diphosphate diacylglycerols are rarely noticed in analyses of lipid compositions of tissues, as they are present is such small amounts (perhaps only 0.05\\% or so of the total phospholipids).

   

CDP-DG(i-13:0/i-16:0)

{[(2R,3R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}({hydroxy[(2R)-3-[(11-methyldodecanoyl)oxy]-2-[(14-methylpentadecanoyl)oxy]propoxy]phosphoryl}oxy)phosphinic acid

C41H75N3O15P2 (911.4673)


CDP-DG(i-13:0/i-16:0) is a cytidine diphosphate diacylglycerol or CDP-diacylglycerol (CDP-DG). CDP-diacylglycerol is an important branchpoint intermediate in eukaryotic phospholipid biosynthesis and could be a key regulatory molecule in phospholipid metabolism. It is a glycerophospholipid in which a cytidine diphosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. CDP-DG(i-13:0/i-16:0), in particular, consists of one chain of isotridecanoic acid at the C-1 position and one chain of isohexadecanoic acid at the C-2 position. Cytidine diphosphate diacylglycerols are rarely noticed in analyses of lipid compositions of tissues, as they are present is such small amounts (perhaps only 0.05\\% or so of the total phospholipids).

   

CDP-DG(i-14:0/a-15:0)

{[(2R,3R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}({hydroxy[(2R)-2-[(12-methyltetradecanoyl)oxy]-3-[(12-methyltridecanoyl)oxy]propoxy]phosphoryl}oxy)phosphinic acid

C41H75N3O15P2 (911.4673)


CDP-DG(i-14:0/a-15:0) is a cytidine diphosphate diacylglycerol or CDP-diacylglycerol (CDP-DG). CDP-diacylglycerol is an important branchpoint intermediate in eukaryotic phospholipid biosynthesis and could be a key regulatory molecule in phospholipid metabolism. It is a glycerophospholipid in which a cytidine diphosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. CDP-DG(i-14:0/a-15:0), in particular, consists of one chain of isotetradecanoic acid at the C-1 position and one chain of anteisopentadecanoic acid at the C-2 position. Cytidine diphosphate diacylglycerols are rarely noticed in analyses of lipid compositions of tissues, as they are present is such small amounts (perhaps only 0.05\\% or so of the total phospholipids).

   

CDP-DG(i-14:0/i-15:0)

{[(2R,3R,5R)-3,4-dihydroxy-5-(2-hydroxy-4-imino-1,4-dihydropyrimidin-1-yl)oxolan-2-yl]methoxy}({hydroxy[(2R)-2-[(13-methyltetradecanoyl)oxy]-3-[(12-methyltridecanoyl)oxy]propoxy]phosphoryl}oxy)phosphinate

C41H75N3O15P2 (911.4673)


CDP-DG(i-14:0/i-15:0) is a cytidine diphosphate diacylglycerol or CDP-diacylglycerol (CDP-DG). CDP-diacylglycerol is an important branchpoint intermediate in eukaryotic phospholipid biosynthesis and could be a key regulatory molecule in phospholipid metabolism. It is a glycerophospholipid in which a cytidine diphosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. CDP-DG(i-14:0/i-15:0), in particular, consists of one chain of isotetradecanoic acid at the C-1 position and one chain of isopentadecanoic acid at the C-2 position. Cytidine diphosphate diacylglycerols are rarely noticed in analyses of lipid compositions of tissues, as they are present is such small amounts (perhaps only 0.05\\% or so of the total phospholipids).

   

CDP-DG(i-15:0/i-14:0)

{[(2R,3R,5R)-3,4-dihydroxy-5-(2-hydroxy-4-imino-1,4-dihydropyrimidin-1-yl)oxolan-2-yl]methoxy}({hydroxy[(2R)-3-[(13-methyltetradecanoyl)oxy]-2-[(12-methyltridecanoyl)oxy]propoxy]phosphoryl}oxy)phosphinate

C41H75N3O15P2 (911.4673)


CDP-DG(i-15:0/i-14:0) is a cytidine diphosphate diacylglycerol or CDP-diacylglycerol (CDP-DG). CDP-diacylglycerol is an important branchpoint intermediate in eukaryotic phospholipid biosynthesis and could be a key regulatory molecule in phospholipid metabolism. It is a glycerophospholipid in which a cytidine diphosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. CDP-DG(i-15:0/i-14:0), in particular, consists of one chain of isopentadecanoic acid at the C-1 position and one chain of isotetradecanoic acid at the C-2 position. Cytidine diphosphate diacylglycerols are rarely noticed in analyses of lipid compositions of tissues, as they are present is such small amounts (perhaps only 0.05\\% or so of the total phospholipids).

   

CDP-DG(i-16:0/a-13:0)

{[(2R,3R,5R)-3,4-dihydroxy-5-(2-hydroxy-4-imino-1,4-dihydropyrimidin-1-yl)oxolan-2-yl]methoxy}({hydroxy[(2R)-2-[(10-methyldodecanoyl)oxy]-3-[(14-methylpentadecanoyl)oxy]propoxy]phosphoryl}oxy)phosphinate

C41H75N3O15P2 (911.4673)


CDP-DG(i-16:0/a-13:0) is a cytidine diphosphate diacylglycerol or CDP-diacylglycerol (CDP-DG). CDP-diacylglycerol is an important branchpoint intermediate in eukaryotic phospholipid biosynthesis and could be a key regulatory molecule in phospholipid metabolism. It is a glycerophospholipid in which a cytidine diphosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. CDP-DG(i-16:0/a-13:0), in particular, consists of one chain of isohexadecanoic acid at the C-1 position and one chain of anteisotridecanoic acid at the C-2 position. Cytidine diphosphate diacylglycerols are rarely noticed in analyses of lipid compositions of tissues, as they are present is such small amounts (perhaps only 0.05\\% or so of the total phospholipids).

   

CDP-DG(i-16:0/i-13:0)

{[(2R,3R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}({hydroxy[(2R)-2-[(11-methyldodecanoyl)oxy]-3-[(14-methylpentadecanoyl)oxy]propoxy]phosphoryl}oxy)phosphinic acid

C41H75N3O15P2 (911.4673)


CDP-DG(i-16:0/i-13:0) is a cytidine diphosphate diacylglycerol or CDP-diacylglycerol (CDP-DG). CDP-diacylglycerol is an important branchpoint intermediate in eukaryotic phospholipid biosynthesis and could be a key regulatory molecule in phospholipid metabolism. It is a glycerophospholipid in which a cytidine diphosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. CDP-DG(i-16:0/i-13:0), in particular, consists of one chain of isohexadecanoic acid at the C-1 position and one chain of isotridecanoic acid at the C-2 position. Cytidine diphosphate diacylglycerols are rarely noticed in analyses of lipid compositions of tissues, as they are present is such small amounts (perhaps only 0.05\\% or so of the total phospholipids).

   

CDP-DG(i-17:0/i-12:0)

{[(2R,3R,5R)-3,4-dihydroxy-5-(2-hydroxy-4-imino-1,4-dihydropyrimidin-1-yl)oxolan-2-yl]methoxy}({hydroxy[(2R)-3-[(15-methylhexadecanoyl)oxy]-2-[(10-methylundecanoyl)oxy]propoxy]phosphoryl}oxy)phosphinate

C41H75N3O15P2 (911.4673)


CDP-DG(i-17:0/i-12:0) is a cytidine diphosphate diacylglycerol or CDP-diacylglycerol (CDP-DG). CDP-diacylglycerol is an important branchpoint intermediate in eukaryotic phospholipid biosynthesis and could be a key regulatory molecule in phospholipid metabolism. It is a glycerophospholipid in which a cytidine diphosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. CDP-DG(i-17:0/i-12:0), in particular, consists of one chain of isoheptadecanoic acid at the C-1 position and one chain of isododecanoic acid at the C-2 position. Cytidine diphosphate diacylglycerols are rarely noticed in analyses of lipid compositions of tissues, as they are present is such small amounts (perhaps only 0.05\\% or so of the total phospholipids).

   

Sar-Arg-Val-Tyr-Val-His-Pro-Ala

2-{[(1-{2-[(2-{[2-({2-[(5-carbamimidamido-1-hydroxy-2-{[1-hydroxy-2-(methylamino)ethylidene]amino}pentylidene)amino]-1-hydroxy-3-methylbutylidene}amino)-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino}-1-hydroxy-3-methylbutylidene)amino]-3-(1H-imidazol-5-yl)propanoyl}pyrrolidin-2-yl)(hydroxy)methylidene]amino}propanoate

C42H65N13O10 (911.4977)


   

PA(22:2(13Z,16Z)/LTE4)

(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-3-{[(2R)-1-[(13Z,16Z)-docosa-13,16-dienoyloxy]-3-(phosphonooxy)propan-2-yl]oxy}-3-oxopropyl]sulphanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C48H82NO11PS (911.5346)


PA(22:2(13Z,16Z)/LTE4) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:2(13Z,16Z)/LTE4), in particular, consists of one chain of one 13Z,16Z-docosadienoyl at the C-1 position and one chain of Leukotriene E4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(LTE4/22:2(13Z,16Z))

(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-3-[(2R)-2-[(13Z,16Z)-docosa-13,16-dienoyloxy]-3-(phosphonooxy)propoxy]-3-oxopropyl]sulphanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C48H82NO11PS (911.5346)


PA(LTE4/22:2(13Z,16Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(LTE4/22:2(13Z,16Z)), in particular, consists of one chain of one Leukotriene E4 at the C-1 position and one chain of 13Z,16Z-docosadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

(2S)-2-amino-3-({[(2R)-2-{[(5Z,7R,8E,10Z,13Z,15E,17S,19Z)-7,17-dihydroxydocosa-5,8,10,13,15,19-hexaenoyl]oxy}-3-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyloxy]propoxy](hydroxy)phosphoryl}oxy)propanoic acid

C50H74NO12P (911.4948)


PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)) is an oxidized phosphatidylserine (PS). Oxidized phosphatidylserines are glycerophospholipids in which a phosphorylserine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylserines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylserines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)), in particular, consists of one chain of one 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl at the C-1 position and one chain of Resolvin D5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PSs can be synthesized via three different routes. In one route, the oxidized PS is synthetized de novo following the same mechanisms as for PSs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PS backbone, mainly through the action of LOX (PMID: 33329396).

   

PS(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

(2S)-2-amino-3-({[(2R)-3-{[(5Z,7S,8E,10Z,13Z,15E,17R,19Z)-7,17-dihydroxydocosa-5,8,10,13,15,19-hexaenoyl]oxy}-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyloxy]propoxy](hydroxy)phosphoryl}oxy)propanoic acid

C50H74NO12P (911.4948)


PS(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) is an oxidized phosphatidylserine (PS). Oxidized phosphatidylserines are glycerophospholipids in which a phosphorylserine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylserines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylserines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PS(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)), in particular, consists of one chain of one Resolvin D5 at the C-1 position and one chain of 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PSs can be synthesized via three different routes. In one route, the oxidized PS is synthetized de novo following the same mechanisms as for PSs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PS backbone, mainly through the action of LOX (PMID: 33329396).

   

PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

(2S)-2-amino-3-({[(2R)-2-{[(4Z,7Z,10R,11E,13Z,15E,17S,19Z)-10,17-dihydroxydocosa-4,7,11,13,15,19-hexaenoyl]oxy}-3-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyloxy]propoxy](hydroxy)phosphoryl}oxy)propanoic acid

C50H74NO12P (911.4948)


PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)) is an oxidized phosphatidylserine (PS). Oxidized phosphatidylserines are glycerophospholipids in which a phosphorylserine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylserines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylserines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)), in particular, consists of one chain of one 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl at the C-1 position and one chain of Protectin DX at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PSs can be synthesized via three different routes. In one route, the oxidized PS is synthetized de novo following the same mechanisms as for PSs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PS backbone, mainly through the action of LOX (PMID: 33329396).

   

PS(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

(2S)-2-amino-3-({[(2R)-3-{[(4Z,7Z,10S,11E,13Z,15E,17R,19Z)-10,17-dihydroxydocosa-4,7,11,13,15,19-hexaenoyl]oxy}-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyloxy]propoxy](hydroxy)phosphoryl}oxy)propanoic acid

C50H74NO12P (911.4948)


PS(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) is an oxidized phosphatidylserine (PS). Oxidized phosphatidylserines are glycerophospholipids in which a phosphorylserine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylserines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylserines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PS(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)), in particular, consists of one chain of one Protectin DX at the C-1 position and one chain of 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PSs can be synthesized via three different routes. In one route, the oxidized PS is synthetized de novo following the same mechanisms as for PSs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PS backbone, mainly through the action of LOX (PMID: 33329396).

   

MC-LA|microcystin-LA

MC-LA|microcystin-LA

C46H69N7O12 (911.5004)


   

Tri-Ac-Leucomycin A1

Tri-Ac-Leucomycin A1

C46H73NO17 (911.4878)


   

2-Methylcitrate

2-Methylcitrate

C7H710O7 (911.5199)


   

(Sar1,Gly8)-Angiotensin II

(Sar1,Gly8)-Angiotensin II

C42H65N13O10 (911.4977)


   

Saralasin

(Sar1,Val5,Ala8)-Angiotensin II

C42H65N13O10 (911.4977)


D057911 - Angiotensin Receptor Antagonists > D047228 - Angiotensin II Type 1 Receptor Blockers C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent

   

Sar-Arg-Val-Tyr-Val-His-Pro-Ala

Sar-Arg-Val-Tyr-Val-His-Pro-Ala

C42H65N13O10 (911.4977)


   

PA(22:2(13Z,16Z)/LTE4)

PA(22:2(13Z,16Z)/LTE4)

C48H82NO11PS (911.5346)


   

PA(LTE4/22:2(13Z,16Z))

PA(LTE4/22:2(13Z,16Z))

C48H82NO11PS (911.5346)


   

PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

C50H74NO12P (911.4948)


   

PS(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

PS(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

C50H74NO12P (911.4948)


   

PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

C50H74NO12P (911.4948)


   

PS(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

PS(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

C50H74NO12P (911.4948)


   

CDP-DG(a-13:0/i-16:0)

CDP-DG(a-13:0/i-16:0)

C41H75N3O15P2 (911.4673)


   

CDP-DG(a-17:0/i-12:0)

CDP-DG(a-17:0/i-12:0)

C41H75N3O15P2 (911.4673)


   

CDP-DG(i-12:0/a-17:0)

CDP-DG(i-12:0/a-17:0)

C41H75N3O15P2 (911.4673)


   

CDP-DG(i-12:0/i-17:0)

CDP-DG(i-12:0/i-17:0)

C41H75N3O15P2 (911.4673)


   
   
   
   

(11s)-14-(2-{[(2r)-2-{[(2r)-2-(n,12-dimethyltetradecanamido)-1,3-dihydroxypropylidene]amino}-1-hydroxypropylidene]amino}-n-methylacetamido)-3,10,13,18-tetrahydroxy-11-methyl-4-nitro-9,12-diazatricyclo[13.3.1.1²,⁶]icosa-1(19),2,4,6(20),9,12,15,17-octaene-8-carboxylic acid

(11s)-14-(2-{[(2r)-2-{[(2r)-2-(n,12-dimethyltetradecanamido)-1,3-dihydroxypropylidene]amino}-1-hydroxypropylidene]amino}-n-methylacetamido)-3,10,13,18-tetrahydroxy-11-methyl-4-nitro-9,12-diazatricyclo[13.3.1.1²,⁶]icosa-1(19),2,4,6(20),9,12,15,17-octaene-8-carboxylic acid

C45H65N7O13 (911.464)


   

14-{2-[(2-{[2-(n,12-dimethyltetradecanamido)-1,3-dihydroxypropylidene]amino}-1-hydroxypropylidene)amino]-n-methylacetamido}-3,10,13,18-tetrahydroxy-11-methyl-4-nitro-9,12-diazatricyclo[13.3.1.1²,⁶]icosa-1(19),2,4,6(20),9,12,15,17-octaene-8-carboxylic acid

14-{2-[(2-{[2-(n,12-dimethyltetradecanamido)-1,3-dihydroxypropylidene]amino}-1-hydroxypropylidene)amino]-n-methylacetamido}-3,10,13,18-tetrahydroxy-11-methyl-4-nitro-9,12-diazatricyclo[13.3.1.1²,⁶]icosa-1(19),2,4,6(20),9,12,15,17-octaene-8-carboxylic acid

C45H65N7O13 (911.464)